350O_PR - Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (...

Date 28 September 2014
Event ESMO 2014
Session Presidential Symposium 1
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer, Metastatic
Presenter Sandra Swain
Citation Annals of Oncology (2014) 25 (5): 1-41. 10.1093/annonc/mdu438
Authors S. Swain1, S. Kim2, J. Cortes3, J. Ro4, V. Semiglazov5, M. Campone6, E. Ciruelos7, J. Ferrero8, A. Schneeweiss9, S. Heeson10, E. Clark10, G. Ross10, M.C. Benyunes11, J. Baselga12
  • 1Medstar Washington Hospital Center, Washington Cancer Institute, 20010 - Washington/US
  • 2Department Of Oncology, Asan Medical Center, KR-138-736 - Seoul/KR
  • 3Breast Cancer Program, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 4Center For Breast Cancer, National Cancer Center, Goyang/KR
  • 5Breast Cancer Department, N.N. Petrov Research Institute of Oncology, RU-197758 - St. Petersburg/RU
  • 6Medical Oncology, Centre René Gauducheau, St Herblain/FR
  • 7Medical Oncology Department, 12 de Octubre University Hospital, Madrid/ES
  • 8Department Of Medical Oncology, Centre Antoine Lacassagne, FR-06189 - Nice CEDEX /FR
  • 9University Hospital, National Center for Tumor Diseases, Heidelberg/DE
  • 10Oncology, Roche Products Limited, Welwyn/GB
  • 11Oncology, Genentech, South San Francisco/US
  • 12Hematology Oncology, Memorial Sloan-Kettering Cancer Center, 10128 - New York/US

 

Abstract

Aim

In CLEOPATRA, 808 pts with HER2-positive MBC were randomized to receive 1L placebo (Pla) + T + D or Ptz + T + D. At primary analysis, pertuzumab was shown to increase progression-free survival significantly, with a strong trend to OS benefit. At a second interim analysis (May 2012), OS was improved to a degree which was both statistically significant and clinically meaningful (HR = 0.66, 95% CI 0.52–0.84; P = 0.0008) but the median OS in pts who received Ptz was not reached. Here we report results of a subsequent prespecified OS analysis.

Methods

This OS analysis was planned when ≥385 deaths were reported. The log-rank test, stratified by prior treatment status and geographic region, was used to compare OS between arms, applying the Lan-DeMets α-spending function with an O'Brien-Fleming threshold of p ≤ 0.0456. The Kaplan–Meier approach was used to estimate median OS in both arms; a stratified Cox proportional hazard model was used to estimate HR and 95% CIs. Subgroup analyses of OS were performed for stratification factors and other key baseline characteristics.

Results

Median follow-up time was 50 months (mos) and the statistically significant improvement in OS in favor of Ptz + T + D was maintained (HR = 0.68, 95% CI 0.56–0.84; p = 0.0002). Median OS was 40.8 mos in the Pla arm and 56.5 mos in the Ptz arm, the difference at the medians being 15.7 mos. The OS benefit in predefined subgroups was consistent with previous observations. It is to be noted that following the previous report of OS benefit, cross-over therapy was allowed and 48 pts in the Pla arm crossed over to the Ptz arm. The safety profile of Ptz + T + D in the overall population and in pts who crossed over to the Ptz arm was consistent with the known safety profile of Ptz and the long-term cardiac safety profile was maintained.

Conclusions

1L treatment with Ptz + T + D significantly improved OS for pts with HER2-positive MBC compared with Pla + T + D, providing a 15.7 mo increase in the median values. The 56.5 mo median OS is unprecedented in 1L MBC and this substantial improvement confirms the Ptz regimen as 1L standard of care for pts with HER2-positive MBC.

Disclosure

S. Swain: acts as an uncompensated consultant for Genentech/Roche. Her institution has received research funding from Genentech/Roche, Pfizer, Puma, Sanofi-Aventis and Bristol-Myers Squibb; S. Kim: has received research funding from Novartis; J. Cortes: has provided consultancy for Novartis, Celgene and Roche and has received honoraria from Novartis, Celgene, Eisai and Roche; M. Campone: has provided consultancy for Novartis/Servier and has received honoraria from Novartis; J. Ferrero: has provided consultancy for Sanofi and has received honoraria from Novartis and Roche; A. Schneeweiss: has provided consultancy for Medac, Celgene and Roche, has received honoraria from Novartis, Celgene, Eisai, Astrazeneca, GlaxoSmithKline, Pfizer and Roche and has received research funding from Roche and Celgene; S. Heeson and G. Ross: is an employee of and owns shares in Roche; E. Clark: is an employee of Roche and owns shares in AstraZeneca; M.C. Benyunes: is an employee of Genentech/Roche; J. Baselga: has provided consultancy for Roche. All other authors have declared no conflicts of interest.